Janux Therapeutics (JANX) Capital Expenditures (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Capital Expenditures of $273000.0 for Q1 2026, up 396.74% year-over-year from $54958.4 in Q1 2025, and up 122.51% quarter-over-quarter from -$1.2 million in Q4 2025.
Powered by 
Analysis
Janux Therapeutics (JANX) Capital Expenditures (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Capital Expenditures for 7 consecutive years, with $273000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 396.74% year-over-year to $273000.0; the TTM figure through Mar 2026 stood at $89000.0 (up 3.49% YoY), while the FY2025 annual figure was -$276000.0, down 173.6% from the prior year.
- Capital Expenditures improved to $273000.0 in Q1 2026 per JANX's latest filing, from -$1.2 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.5 million in Q2 2022 and bottomed at -$1.2 million in Q4 2025.
- Historically, Capital Expenditures has averaged $205411.8 across 5 years, with a median of $285000.0 in 2023.
- Annual changes were most pronounced in 2022 — Capital Expenditures sank 891.3% — and 2025, when it jumped 885.26%.
- Janux Therapeutics' Capital Expenditures stood at $313000.0 in 2022, then surged by 64.54% to $515000.0 in 2023, then plunged by 35.34% to $333000.0 in 2024, then tumbled by 464.26% to -$1.2 million in 2025, then jumped by 122.51% to $273000.0 in 2026.
- Business Quant data shows JANX's Capital Expenditures at $273000.0 in Q1 2026, -$1.2 million in Q4 2025, and $93000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Janux Therapeutics | 1.27 Bn | 1.27 Bn | - | -861,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -861,000.00 |
| Mar 31, 2026 | 1.34 Mn |
| Dec 31, 2025 | 106,000.00 |
| Sep 30, 2025 | 93,000.00 |
| Jun 30, 2025 | 473,000.00 |
| Mar 31, 2025 | 371,000.00 |
| Dec 31, 2024 | 58,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Jun 30, 2024 | 95,000.00 |
| Mar 31, 2024 | 197,000.00 |
| Dec 31, 2023 | 515,000.00 |
| Sep 30, 2023 | 292,000.00 |
| Jun 30, 2023 | 648,000.00 |
| Mar 31, 2023 | 395,000.00 |
| Dec 31, 2022 | 2.06 Mn |
| Sep 30, 2022 | 2.52 Mn |
| Jun 30, 2022 | 898,000.00 |
| Mar 31, 2022 | 971,000.00 |
| Dec 31, 2021 | 629,000.00 |
| Sep 30, 2021 | 621,000.00 |